Journal article · 2026

Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors

Tammy Ladduwahetty, Benjamin F. Rahemtulla, Eric P. A. Talbot, Joseph Bateman, Neil Benson, 陈鹏源, Xiaoling F. Cockcroft, Li Feng, Elnaz Gozalpour, Kui Lin, Mustafa Moroglu, Yi Qin and 13 more

Journal of Medicinal Chemistry, 69(21), 25361–25378 · Published 17 October 2026 · DOI 10.1021/acs.jmedchem.6c01265

View at the publisherCite this paper

In brief

“Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors” is a 2026 journal article by Tammy Ladduwahetty and 24 co-authors, published in Journal of Medicinal Chemistry. OpenAlex counts 1 citations as of 16 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.40
References
35
Authors
25

Abstract

Hematological toxicities have resulted in limiting the dose of first-generation PARP inhibitors, which have activity at both PARP1 and PARP2. With the advancement of selective PARP1 inhibitors to the clinic, we embarked on a program to identify novel PARP1 inhibitors that are suitable for the treatment of CNS malignancies. Central to our design was the… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Ladduwahetty, T., Rahemtulla, B. F., Talbot, E. P. A., Bateman, J., Benson, N., 陈鹏源, Cockcroft, X. F., Feng, L., Gozalpour, E., Lin, K., Moroglu, M., Qin, Y., Raoshan, E., Ratnam, J., Shen, Y., Sollis, S., Tong, Z., Wang, T., Westwood, M., . . . Foote, K. M. (2026). Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of Medicinal Chemistry, 69(21), 25361–25378. https://doi.org/10.1021/acs.jmedchem.6c01265

MLA 9

Ladduwahetty, Tammy, et al. “Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors.” Journal of Medicinal Chemistry, vol. 69, no. 21, 2026, pp. 25361–25378. https://doi.org/10.1021/acs.jmedchem.6c01265.

Chicago

Ladduwahetty, Tammy, Benjamin F. Rahemtulla, Eric P. A. Talbot, Joseph Bateman, Neil Benson, 陈鹏源, Xiaoling F. Cockcroft, et al. 2026. “Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors.” Journal of Medicinal Chemistry 69 (21): 25361–25378. https://doi.org/10.1021/acs.jmedchem.6c01265.

Harvard

Ladduwahetty, T. et al. (2026) ‘Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors’, Journal of Medicinal Chemistry, 69(21), pp. 25361–25378. doi:10.1021/acs.jmedchem.6c01265.

IEEE

T. Ladduwahetty et al., “Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors,” Journal of Medicinal Chemistry, vol. 69, no. 21, pp. 25361–25378, 2026, doi: 10.1021/acs.jmedchem.6c01265.

BibTeX

@article{ladduwahetty2026discovery,
  title     = {{Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors}},
  author    = {Ladduwahetty, Tammy and Rahemtulla, Benjamin F. and Talbot, Eric P. A. and Bateman, Joseph and Benson, Neil and 陈鹏源 and Cockcroft, Xiaoling F. and Feng, Li and Gozalpour, Elnaz and Lin, Kui and Moroglu, Mustafa and Qin, Yi and Raoshan, Emily and Ratnam, Joseline and Shen, Yang and Sollis, Steve and Tong, Zixuan and Wang, Tingzhong and Westwood, Marta and Xie, Yiming and Yeap, Siew Kuen and Rui, Yuan and Watt, Gillian F. and Taylor, Simon and Foote, Kevin M.},
  journal   = {Journal of Medicinal Chemistry},
  year      = {2026},
  volume    = {69},
  number    = {21},
  pages     = {25361--25378},
  doi       = {10.1021/acs.jmedchem.6c01265},
  url       = {https://doi.org/10.1021/acs.jmedchem.6c01265}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy

  • PARP-1 inhibitors
  • oral bioavailability
  • drug efflux
  • hematologic toxicity
  • CNS malignancies
  • tumor growth inhibition
  • pharmacokinetic-pharmacodynamic modeling
  • once-daily dosing

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Ladduwahetty, T., Rahemtulla, B. F., Talbot, E. P. A., Bateman, J., Benson, N., 陈鹏源, Cockcroft, X. F., Feng, L., Gozalpour, E., Lin, K., Moroglu, M., Qin, Y., Raoshan, E., Ratnam, J., Shen, Y., Sollis, S., Tong, Z., Wang, T., Westwood, M., . . . Foote, K. M. (2026). Discovery of Potent, Orally Bioavailable, and CNS-Penetrant 1,2,3-Triazolopyridinyl Piperazine-Based PARP1-Selective Inhibitors. Journal of Medicinal Chemistry, 69(21), 25361–25378. https://doi.org/10.1021/acs.jmedchem.6c01265

How many times has this paper been cited?

1 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Tammy Ladduwahetty, Benjamin F. Rahemtulla, Eric P. A. Talbot, Joseph Bateman, Neil Benson, 陈鹏源, Xiaoling F. Cockcroft, Li Feng, Elnaz Gozalpour, Kui Lin, Mustafa Moroglu, Yi Qin and 13 more.

What is the DOI of this paper?

10.1021/acs.jmedchem.6c01265, permanently at https://doi.org/10.1021/acs.jmedchem.6c01265. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.